The effects of prostaglandin E1 on hepatic allograft vascular inflow: A prospective randomized double-blind study

American Surgeon

Volumn 62, Issue 3, 1996, Pages 184-187

  Chavin, Kenneth D ^a   Uber, Lynn ^a   Baliga, Prabhakar ^a   Rajagopalan, P ^a   Cofer, Joseph B ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTAGLANDIN E1;

ADULT; ARTERY BLOOD FLOW; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GRAFT FAILURE; HUMAN; LIVER FAILURE; LIVER TRANSPLANTATION; MALE; MAXIMUM PERMISSIBLE DOSE; MULTICENTER STUDY; PORTAL VEIN BLOOD FLOW; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

ADULT; ALPROSTADIL; BLOOD FLOW VELOCITY; BLOOD PRESSURE; DOUBLE-BLIND METHOD; FEMALE; HEPATIC ARTERY; HUMANS; LIVER CIRCULATION; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PORTAL VEIN; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES;

EID: 0029934227     PISSN: 00031348     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Shaw S, Gordon R, Iwatsuki S, et al. Hepatic retransplantation. Transplant Proc 1985:17:264-6.
2. Greig PD, Woolf GM, Sinclair SB, et al. Treatment of primary liver graft nonfunction with prostaglandin E1. Transplantation 1989;48:447-53.
3. Abecassis M, Falk R, Blendis L. Treatment of fulminant hepatic failure with a continuous infusion of Prostin-VR (PGE1). Hepatology 1987;7:1104-9.
4. Greig PD, Woolf GM, Abecassis M, et al. Prostaglandin E1 for primary nonfunction following liver transplantation. Transplant Proc 1989;21:3360-1.
5. Isai H, Sheil AG, McCaughan G, et al. Successful reversal of primary graft non-function in a liver transplant patient treated with prostaglandin E1. Aust N Z J Surg 1992;62:314-6.
6. Mollison LC, Angus PW, Jones RM. Prostaglandin E1 for the treatment of primary non-function of the donor organ in liver transplantation. Med J Aust 1991;155:51-3.
7. c Congres international d'Angelogie 1955;1:263-5.
8. Van HJ, Bernatz PE. Application of the square-wave electromagnetic flowmeter to clinical surgery. Mayo Clin Proc 1969; 44:184-92.
9. Cofer JB, Klintmalm GB, Howard TK, et al. A comparison of UW with Eurocollins preservation solution in liver transplantation. Transplantation 1990;49:1088-93.
10. Quiroga J, Prieto J. Liver cytoprotection by prostaglandins. Pharmacol Ther 1993;58:67-91.
11. Gaber AO, Thistlethwaite JJ, Busse HS, et al. Improved results of preservation of hepatic grafts preflushed with albumin and prostaglandins. Transplant Proc 1988;20:992-3.
12. Kurokawa T, Nonami T, Harada A, et al. Effects of prostaglandin E1 on the recovery of ischemia-induced liver mitochondrial dysfunction in rats with cirrhosis. Scand J Gastroenterol 1991;26:269-74.
13. Masaki N, Ohta Y, Shirataki H, et al. Hepatocyte membrane stabilization by prostaglandins E1 and E2: favorable effects on rat liver injury. Gastroenterology 1992;102:572-6.
14. Garcia VJ, Rull R, Angas J, et al. Prostaglandin metabolism and hemodynamic alterations during human liver transplantation. Transplant Proc 1993;25:1861-2.
15. Husberg BS, Genyk YS, Klintmalm GB. A new rat model for studies of the ischemic injury after transplantation of fatty livers: improvement after postoperative administration of prostaglandin. Transplantation 1994;57:457-8.